{
    "clinical_study": {
        "@rank": "112772", 
        "acronym": "ALGOFINE-2", 
        "arm_group": [
            {
                "arm_group_label": "IN Sufentanil AND IV Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration"
            }, 
            {
                "arm_group_label": "IV Morphine AND IN Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray"
            }
        ], 
        "brief_summary": {
            "textblock": "Intranasal (IN) administration of opiates is an appealing non-invasive way of treating acute\n      traumatic pain in prehospital and Emergency departments (ED).\n\n      The investigators hypothesize that IN administration of Sufentanil is equal as compared with\n      Intra veinous (IV) administration of Morphine wich is widely recommended in ED.\n\n      The investigators study is a multicentric, comparative, randomized, double-blind,\n      double-placebo study, comparing quality of analgesia in both groups  30 minutes after first\n      administration of opiates.\n\n      The investigators also asses side effects and patient satisfaction in both groups."
        }, 
        "brief_title": "Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Severe Traumatic Pain", 
            "Numeric Pain Rating Scale > 5 / 10"
        ], 
        "condition_browse": {
            "mesh_term": "Emergencies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Traumatic pain\n\n          -  Numeric Pain Rating Scale (NPRS) >5 /10\n\n          -  Age between 18 and 75 years old\n\n        Exclusion Criteria:\n\n          -  Medical pain (headache, chest pain,...)\n\n          -  Respiratory, renal or hepatic insufficiency\n\n          -  Drug addiction\n\n          -  Medical or Chirurgical sinus history\n\n          -  Oxygene saturation < 90%\n\n          -  Systolic blood pressure < 90mmHg\n\n          -  Head injury with a neurological Glasgow Coma Scale (GCS) < 14\n\n          -  Opioid allergy\n\n          -  Facial traumatism\n\n          -  Patient unable do understand or assessing NPRS\n\n          -  Opiates administration within  6 hours before admission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "220", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02095366", 
            "org_study_id": "ALGOFINE-2"
        }, 
        "intervention": [
            {
                "arm_group_label": "IV Morphine AND IN Placebo", 
                "description": "Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.\nPain is controlled by:\nat 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg\nat 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV  0,05mg/kg\nat 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV  0,05mg/kg", 
                "intervention_name": "Morphine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IN Sufentanil AND IV Placebo", 
                "description": "Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.\nPain is controlled by:\nat 0 minute : Sufentanil IN 0,3\u00b5g/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV\nat 10 minutes and if NPRS>3 : Sufentanil IN 0,15\u00b5g/kg (1 spray) + NaCl 0,9% IV\nat 20 minutes and if NPRS>3: Sufentanil IN 0,15\u00b5g/kg (1 spray) + NaCl 0,9% IV", 
                "intervention_name": "Sufentanil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IN Sufentanil AND IV Placebo", 
                "description": "Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.\nPain is controlled by:\nat 0 minute : Sufentanil IN 0,3\u00b5g/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV\nat 10 minutes and if NPRS>3 : Sufentanil IN 0,15\u00b5g/kg (1 spray) + NaCl 0,9% IV\nat 20 minutes and if NPRS>3: Sufentanil IN 0,15\u00b5g/kg (1 spray) + NaCl 0,9% IV", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "saline solution", 
                    "NaCl 0.9%"
                ]
            }, 
            {
                "arm_group_label": "IV Morphine AND IN Placebo", 
                "description": "Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.\nPain is controlled by:\nat 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg\nat 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV  0,05mg/kg\nat 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV  0,05mg/kg", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "saline solution", 
                    "NaCl 0.9%"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Morphine", 
                "Sufentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute Pain", 
            "Traumatic Pain", 
            "Emergency setting", 
            "Prehospital setting", 
            "Analgesia", 
            "Intranasal device", 
            "Intra veinous injection", 
            "Sufentanil citrate", 
            "Morphine Sulfate"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Annecy", 
                        "country": "France"
                    }, 
                    "name": "Emergency Department - Hospital Annecy"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chambery", 
                        "country": "France"
                    }, 
                    "name": "Emergency Department - Hospital Chamb\u00e9ry"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France"
                    }, 
                    "name": "Emergency Department - University Hospital of Grenoble"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Voiron", 
                        "country": "France"
                    }, 
                    "name": "Emergency Department - Hospital Voiron"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting. A Multicenter,Randomized,Controled, Comparative, Double Blinded Study", 
        "overall_contact": {
            "email": "MBlancher@chu-grenoble.fr", 
            "last_name": "Marc BLANCHER, MD"
        }, 
        "overall_contact_backup": {
            "email": "CClape@chu-grenoble.fr", 
            "last_name": "Cyrielle CLAPE, CRA"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patient self-assessed pain intensity using Numeric Pain Rating Scale (0 to 10). 30 minutes after the first opiate administration.", 
            "measure": "Efficiency of Analgesia", 
            "safety_issue": "No", 
            "time_frame": "30 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02095366"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University Hospital, Grenoble", 
            "investigator_full_name": "AdministrateurDRC", 
            "investigator_title": "Delegation de la recherche clinique et de l'innovation", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Sedation Score, Breathing Rate, Oxygen Saturation, Arterial Blood Pressure, Heart rate, Nasal Ulceration.\nProportion of patients having opioid-related side effects.", 
                "measure": "Opioid-related side effects", 
                "safety_issue": "Yes", 
                "time_frame": "10 minutes"
            }, 
            {
                "description": "Patient self-assessed pain intensity using Numeric Pain Rating Scale (0 to 10). 10 minutes  and 20 minutes after the first opiate administration.", 
                "measure": "Efficiency of Analgesia", 
                "safety_issue": "No", 
                "time_frame": "Every 10 minutes"
            }, 
            {
                "measure": "Patient Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "40 min"
            }, 
            {
                "description": "Patient self-assessed pain intensity, using Numeric Pain Rating Scale (0 to 10) at 10, 20 and 30 min after the first opiate administration", 
                "measure": "Specific Analysis for the pre hospital setting group: Efficiency of Analgesia", 
                "safety_issue": "No", 
                "time_frame": "Every 10 minutes"
            }
        ], 
        "source": "University Hospital, Grenoble", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fondation Apicil", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "SFMU", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital, Grenoble", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}